Table 5.

Peripheral blood Tregsa pre- and postvaccination

PatientSample% Tregs in CD4+Ratio of Teffs:Tregsb
Breast cancer patients
1Pre5.312.5:1
D1313.917.8:1
8Pre2.435.1:1
D442.522.5:1
12Pre2.628.9:1
D275.113.1:1
13Pre8.27.5:1
D41611.5:1
23Pre322.3:1
D702.329.3:1
24Pre4.213.6:1
D715.910.4:1
Ovarian cancer patients
2Pre3.321.8:1
D714.216.9:1
3Pre4.516.2:1
D284.016.9:1
5Pre3.121.6:1
D703.717.7:1
7Pre6.29.2:1
D764.214.2:1
10Pre6.49.1:1
D773.417.7:1
11Pre3.817:1
D764.414:1
14Pre5.113.5:1
D714.017.5:1
19Pre2.423.3:1
D693.118.3:1

Bold font indicates decreases in Tregs or increases in Teffs:Tregs.

  • aTregs (T regulatory cells) defined as CD4+CD25highFoxp3+, percentage of CD4+CD25highFoxp3+ in CD4+ cells.

  • bRatio of Teffs (T effector cells; CD4+CD25) to Tregs (CD4+CD25highFoxp3+).